Julie Kim

  PhotoJulie Kim is currently the Global Franchise Head for the BioTherapeutics Franchise and has been with Baxter since 2001. The BioTherapeutics Franchise includes a portfolio of antibody-replacement therapies, albumin and a number of specialty plasma proteins that are available globally. Development programs within BioTherapeutics include HyQvia (a new, facilitated subcutaneous administration of Ig), new formulations and indications for GAMMAGARD LIQUID/KIOVIG, and exploration of new plasma proteins. Kim has an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a BA in Economics from Dartmouth College.